Treatment guidelines in polycythemia vera currently recommend maintaining hematocrit below 45%, with a higher threshold for ...

Topline data were announced from a phase 3 trial evaluating rusfertide in patients with polycythemia vera (PV ... in 293 PV patients with uncontrolled hematocrit who are phelobotomy-dependent ...

A panelist discusses how they prioritize specific clinical and laboratory parameters when assessing response to first-line ...

Many people with polycythemia vera (PV) live a normal life with this rare blood cancer under control. The goal is to avoid complications like blood clots, which may happen because PV thickens your ...

The reduction of hematocrit below 45% is a primary treatment ... placebo-controlled trial evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period.

Many patients with polycythemia vera, the news release noted ... undergo phlebotomy — described as a process of removing blood to manage elevated levels of hematocrit, or the percentage of red blood ...

He anticipates that rusfertide will not only normalize iron levels and control hematocrit (HcT ... a treatment for polycythemia vera. Protagonist Therapeutics is advancing its lead candidate ...

Polycythemia vera is a type of blood cancer ... The other three pre-specified key secondary endpoints, namely hematocrit control and patient-reported outcomes using PROMIS Fatigue SF-8a3 and ...

An expert discusses how the positive efficacy findings from the phase 3 RESPONSE trial, showing high rates of hematocrit control and spleen response with ruxolitinib vs standard therapy in hydroxyurea ...

The primary endpoint of the study was met, with a significantly higher proportion of clinical responders 1 among rusfertide-treated patients with PV (77%) compared to those who received placebo ...

The reduction of hematocrit below 45% is a primary treatment goal for ... placebo-controlled trial evaluating rusfertide in 293 patients with polycythemia vera over a 156-week period. The trial is ...